Gunsynd PLC - Investee Company Update – Aberdeen Minerals Ltd
Announcement provided by
Gunsynd Plc · GUN11/10/2023 07:00
Gunsynd plc
("Gunsynd" or the "Company")
Investee Company Update - Aberdeen Minerals Ltd
Gunsynd Plc (AIM: GUN, AQSE: GUN) is pleased to announce that it has received an update from its investee company Aberdeen Minerals Ltd ("
Innovations to be tested include Glycine Leaching Technology, a technique patented by Draslovka, which uses glycine, a non-toxic amino acid often used as a food additive or nutritional supplement in humans and animals, as an environmentally sustainable and cost-effective way to produce critical minerals.
The ATF is delivered by the Advanced Propulsion Centre ("APC") in collaboration with the Department for Business and Trade and Innovate
Gunsynd subscribed for 2,000,000 shares at
More information can be found on
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the Company's ability to execute and implement future plans, and the occurrence of unexpected events. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors.
For further information please contact:
Gunsynd plc Hamish Harris/ Peter Ruse
|
+44 (0) 78 7958 4153 |
Cairn Financial Advisers LLP James Caithie / Liam Murray |
+44 (0) 20 7213 0880
|
Peterhouse Capital Limited Lucy Williams |
+44 (0) 20 7469 0936
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.